MetLife MET
Financial Services · Insurance - Life · Synthos Deep Dive · 2026-07-03
The Overview
MetLife is one of the biggest life-insurance and employee-benefits companies in the world — the "Snoopy" company your employer's dental, disability, and life insurance often runs through. It collects premiums, invests a giant ~$466 billion pile of bonds and loans, and pockets the spread. It's been around since 1863.
Is the stock cheap or expensive? Cheap. You're paying about 9 times next year's expected profit — roughly half what the average big company costs — plus you collect a ~2.5% dividend and the company keeps buying back its own shares. That's the appeal.
The catch: insurers like this don't grow fast. Sales barely move year to year, and the profit growth mostly comes from buying back stock and from Asia. It's a steady, boring cash machine, not a rocket. Our verdict is Buy — Tactical: a reasonable value-and-income holding, sized small.
Here's what the three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe, with a catch). It's cheap, has more cash than debt at the parent, and the stock is calm. But the whole business is a huge bond-and-loan portfolio, so a sharp move in interest rates or a wave of loan defaults could dent it.
- Growth Quality 5/10 (middling). Solid, profitable, well-run — but slow-growing, and a chunk of the "growth" is just share buybacks.
- Exponential Potential 3/10 (low). This is a mature giant in a slow industry. Don't expect it to double quickly.
The one big worry: MetLife's profits ride on a massive investment portfolio — bonds, private credit, commercial real-estate loans, and long-dated pension liabilities. A rate shock or a credit blow-up would hit its book value quickly.
Putting a number on it: our fair-value estimate is $99 against a current price of $96.51 — real upside if our numbers are right.
Our summary metrics
Cheap (9× fwd adj-EPS), net-cash holdco, beta 0.78 — but rate-sensitive spread book, big illiquid-asset & PRT tail, GAAP earnings noisy.
~9% fwd adj-EPS CAGR is mostly buybacks + Asia; low single-digit revenue growth, mid-teens ROE, no real moat.
A mature $58B life insurer in a low-growth industry; steady compounder, not an exponential — decelerating revenue, capped room to run.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A mature $58B life insurer in a low-growth industry; steady compounder, not an exponential — decelerating revenue, capped room to run.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $94.86 (high $102 / low $90; 25 Buy · 8 Hold · 0 Sell) — context, not our anchor |
| Valuation | ~9.1× FY26E adj-EPS · 8.2× FY27E · 6.7× FY29E · P/B 2.15× · EV/EBITDA 9.4× · EV/Sales 0.72× · div yield ~2.5% |
| Technicals | Uptrend — $90.06 at the 52-wk high, above 50/200-DMA, RSI 57, but +11% 12-mo lags SPY +21% |
| Conviction | Low — zero expert voices in the Synthos KB; call rests entirely on fundamentals + quant |
| Position sizing | Value/income satellite, ~1–3%; a defensive financial, not a core conviction position |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for MET — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $96.51, 3% above the 50-day average ($93), 18% above the 200-day average ($81) — an uptrend. 3% below the 52-week high of $100, 43% above the 52-week low of $68.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $96.51 is currently inside the band (band $94–$99).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 55.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.28, negative momentum.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = MET · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
MetLife, Inc. (NYSE: MET) is a ~160-year-old global life-insurance, annuities, employee-benefits, and asset-management company headquartered in New York, founded 1863, IPO'd 2000. It runs through five reporting pillars — U.S. (Group Benefits + Retirement & Income Solutions), Asia, Latin America, EMEA, and MetLife Holdings — plus MetLife Investment Management (MIM), its ~$600B+ third-party asset manager. Products span group and individual life, dental, disability, vision, accident & health, annuities (fixed/indexed/variable), pension risk transfer (PRT), institutional income annuities, and stable-value/funding-agreement products. Fiscal year ends December 31. CEO: Michel Khalaf.
A note on the accounting: an insurer's GAAP net income is noisy — it runs market-value swings on investments and hedges through the P&L. MetLife (like the analyst community) steers on adjusted earnings, which strips those items. Two consequences matter for this note:
- FY25 GAAP EPS was $4.80 (net income $3.38B on $77.1B revenue), but adjusted EPS was ~$8.7 and FY26E consensus adjusted EPS is $9.91. The valuation multiples below use the adjusted (analyst-estimate) series, which is the honest apples-to-apples number; GAAP P/E (~17×) overstates the true earnings multiple.
- Revenue itself is a weak lever here — premiums, fees, and net investment income move slowly. The earnings story is margins, the investment portfolio, and share count.
Revenue mix (FY2023 segment view, from filings — the most recent full segment breakout FMP provides):
- By segment: Group Benefits $25.2B, Retirement & Income Solutions (RIS) $16.6B, Asia $10.9B, MetLife Holdings $8.2B, Latin America $7.4B, EMEA $2.5B, Corporate & Other $0.8B (reconciling −$4.8B).
- By geography (FY2023): United States $50.1B (~73%), Asia $10.9B, Latin America $7.4B, EMEA $2.5B. US-concentrated, with Asia and Latin America the faster-growing international legs. (FMP's FY24/FY25 segment fields are sparse; the FY23 breakout is the cleanest full picture.)
The strategic frame management pushes ("New Frontier" plan): grow Group Benefits and Asia, expand MIM's fee income, hold a disciplined ~12% direct-expense ratio, target 15–17% adjusted ROE, and return capital aggressively via buybacks and a growing dividend.
2. The expert thesis
There is no expert coverage of MetLife in the Synthos knowledge base. total_claims = 0; zero net-bullish or cautionary voices. Unlike a conviction-track name, nothing here is backed by a distilled, skill-weighted expert panel.
What that means for this note (stated plainly): the verdict is fundamentals- and quant-driven only. Every judgment below is derived from the FMP financials, analyst estimates, the price/technical block, and MetLife's own SEC-filed earnings materials — not from Synthos expert claims. No claim_id values are cited because none exist. Absence of KB coverage is not a negative signal (MetLife is simply outside the expert panel's focus, which skews toward high-growth/tech and biotech); it just means conviction is capped at Low and the call leans on hard numbers rather than a differentiated informational edge. Read this as a quantitative value screen with a full financial workup, not a high-conviction thesis.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Moderate-Low | Cheap (9× fwd adj-EPS, 2.15× book), holdco net-cash (net debt −$1.85B, net-debt/EBITDA −0.4×), beta 0.78, RBC 379% vs 360% target. Offsetting: earnings ride a ~$466B spread portfolio (private credit, CRE, PRT longevity tail) that a rate/credit shock hits fast; GAAP earnings volatile. |
| Growth Quality | 5 · Average | ~9% forward adj-EPS CAGR, but revenue barely grows and much of EPS growth is buyback-driven; ROE ~13% GAAP / 15–17% adjusted is respectable-not-elite; no durable moat beyond scale and distribution. Solid, unspectacular. |
| Exponential Potential | 3 · Low | Mature life insurer in a low-single-digit-growth industry; revenue decelerating, $58B cap in a saturated market. A steady compounder, structurally not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. All EPS below are adjusted (the analyst-estimate series).
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Asia + Group Benefits keep compounding, VII (variable investment income) normalizes higher, buybacks shrink the share count faster; FY27E adj-EPS beats to ~$11.5 and the market re-rates a de-risked insurer to ~10.5×. | ~$122 (+35%) |
| Base (our anchor) | Estimates roughly hit — FY27E adj-EPS ~$11.0; a cheap, well-capitalized insurer earns a modest re-rate to ~9.0× (from ~9.1× fwd today) as capital return continues. | ~$99 (+10%) |
| Bear | Rate shock or credit event hits the investment book and book value; PRT/long-tail reserve strengthening; adj-EPS stalls near ~$9 and the multiple stays depressed at ~8×. | ~$72 (−20%) |
Synthos fair value = the base case, ~$99 (+10%), with the full $72–$122 span as the honest range. Our base sits a touch above the Street's $94.86 consensus (we give modest credit to continued buybacks and Asia), while our bear is below the Street's $90 low (we take the spread-book tail seriously). Note the Street's low is at today's price — the sell-side sees limited downside, which is itself a mild caution that the easy value has partly been recognized. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MET is neither an exponential nor even a fast compounder — it is a mature, low-growth value/income insurer:
- Forward growth: revenue CAGR FY25→FY29E is only ~4.7% ($77B → ~$93B); adjusted-EPS CAGR is a better ~9% ($9.91 FY26E → $13.50 FY29E), but the gap between the two is the tell — EPS growth is manufactured by buybacks and margin, not by the business getting bigger.
- Acceleration (2nd derivative) is flat-to-negative: analyst revenue path decelerates ($80.6B FY26E → $84.0B FY27E → $87.6B FY28E → $92.9B FY29E, i.e. ~4–5%/yr and easing). There is no inflection to ride.
- Room to run: the US life/benefits market is mature and saturated; the genuine runway is Asia and MIM fee income, but neither is large enough to move a $58B enterprise into multibagger territory. TAM is not the constraint that matters — this is a share/margin game, not a land-grab.
- Reinvestment runway: capital is returned (buybacks + dividend), not plowed into a high-ROIC reinvestment flywheel — the opposite of an exponential's profile, and entirely appropriate for a mature insurer.
Exponential Potential: Low (3/10). Own MET for cheapness, dividend, and buyback-driven per-share compounding — not for growth. This honest framing is why it lands in the value/income satellite sleeve, never the exponential tier.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $77.08B, +10.2% (FY24 $69.94B, FY23 $67.71B). The jump is partly PRT/annuity-driven premium timing, not a durable acceleration — the estimate series has revenue back to ~4–5%/yr.
- GAAP earnings (noisy): FY25 net income $3.38B, GAAP EPS $4.80 — down from FY24's $4.42B / $5.98 despite higher revenue, reflecting investment/actuarial mark volatility. This is why GAAP P/E (~17×) is misleading for an insurer.
- Adjusted earnings (the steering metric): Q1'26 adjusted EPS $2.42 (+23% YoY), adjusted earnings $1.59B; TTM adjusted EPS runs ~$9.3. FY26E consensus adjusted EPS $9.91.
- Margins & returns: net profit margin ~4.5% TTM (thin, as expected for a spread business), ROE ~12.9% GAAP / 15–17% adjusted (company target), ROA ~0.5% (leverage is inherent to insurance).
- Cash flow: operating cash flow $18.1B FY25 (up from $15.1B), effectively all free cash flow (minimal capex) — funds a ~$3.9B FY25 buyback and ~$1.5B common dividend.
- Balance sheet: total investments ~$466B; total debt $20.2B against $22.0B cash → net cash of ~$1.85B at the holdco, net-debt/EBITDA −0.4×. Total equity $28.9B; book value/share ~$42.6, so the stock trades at ~2.15× book. NAIC RBC ratio 379% (vs 360% target) — well-capitalized.
The honest tell: the business is financially sturdy and returns a lot of cash, but it is a balance-sheet business — the ~$466B investment portfolio (private credit, ~$41.5B commercial mortgage loans, structured products, PRT longevity liabilities) is where both the earnings and the risk live. Watch credit and rates, not revenue.
6. Valuation — priced in or room?
On the adjusted (analyst-estimate) earnings series, MET is genuinely cheap: forward P/E ~9.1× FY26E → 8.2× FY27E → 6.7× FY29E, versus a market multiple two to three times that. Supporting reads: P/B 2.15×, EV/EBITDA 9.4×, EV/Sales 0.72×, FCF yield very high (mechanically inflated by insurance float, so weight it lightly), dividend yield ~2.5% with a ~46% payout. The FMP letter rating is B+.
The reason it's cheap is not mispricing so much as what it is: a low-growth, rate-sensitive, capital-intensive insurer whose GAAP earnings swing and whose book value is exposed to credit and rate marks. Insurers structurally trade at low multiples; MET is roughly in line with its life-insurer peer group, not a hidden gem. The value case is real but modest — you're paid a ~2.5% dividend plus buyback shrinkage to hold a well-run compounder at a single-digit multiple, with a re-rate as upside optionality rather than the base case. Street targets (context): consensus $94.86, high $102, low $90 (25 Buy / 8 Hold / 0 Sell). Our ~$99 base is modestly above consensus; this is a cheap-quality-insurer buy, not a deep-value or growth buy.
7. Technicals (from the FMP tech block)
- Trend: up. $90.06 sits above the 50-DMA ($82.62) and 200-DMA ($78.47), 50 above 200 (golden-cross posture). MACD +1.33 (positive).
- Location: at the 52-week high ($90.06), +33% off the 52-week low ($67.33), essentially zero drawdown from peak — a name breaking out to new highs.
- Momentum: RSI(14) 57 — constructive, not overbought (<70), so no stretched-entry warning.
- Relative strength (the caution): MET +11.1% 12-mo vs SPY +20.6% and QQQ +30.3% — it has lagged the market over a year even while grinding higher, consistent with a defensive value name. Shorter-term it's caught up: +26.5% 3-mo vs SPY +13.7%.
- Read: technicals are healthy (uptrend, new highs, not overbought), but the 12-month lag vs the index confirms this is a defensive/value holding, not a momentum leader. No technical reason to avoid; a pullback toward the rising 50-DMA (~$83) would be a lower-risk add.
8. Moat & competitive position
MetLife's edge is scale and distribution, not a durable economic moat. In Group Benefits it is a US market leader with deep employer/broker relationships and a data advantage in underwriting; in Asia and Latin America it has established, hard-to-replicate franchises; MIM adds ~$600B+ of fee-earning AUM. But life insurance is fundamentally a commodity spread business — products are substitutable, switching is driven by price and ratings, and returns are capped by competition and regulation. There is no pricing-power moat comparable to a branded consumer or software franchise. The competitive frame is a fragmented oligopoly of large life insurers competing on capital strength, distribution, and investment performance.
Peer set (FMP peers, market cap): Aflac $61.5B, Manulife $68.7B, Prudential Financial (PRU) $39.2B, Prudential plc $34.4B, Globe Life $14.0B, Unum $14.8B, Jackson Financial $7.3B, Lincoln National $7.1B, CNO Financial $4.9B, Brighthouse (its own former spin-off) $2.4B. Against this group MET is among the largest and best-capitalized, trades at a broadly comparable low multiple, and screens as a quality name within a structurally low-multiple industry.
9. Management, capital allocation & guidance
- Capital allocation: shareholder-friendly and disciplined — FY25 returned ~$3.9B via buybacks and ~$1.5B in common dividends; Q1'26 alone returned ~$1.1B (~$750M buyback + ~$370M dividend). Share count has fallen from ~893M (FY20) to ~652M (Q1'26) — a ~27% reduction in five years, the primary engine of per-share growth. Net-debt/EBITDA is negative (net cash at holdco).
- Insider activity: the recent Form 4s (filed 2026-06-18) are routine director equity awards at ~$87.40, not open-market conviction buys or a cluster of discretionary selling — a neutral signal.
- Management's own guidance (half-weighted — their self-interested words): from MetLife's SEC-filed Q1'26 earnings-call presentation (filed 2026-05-06), management reiterated its "New Frontier" framework and near-term targets: adjusted ROE target 15–17% (Q1'26 came in at 17.0%, top of range); direct expense ratio ~12.1% target (Q1'26 at 11.9%, ahead of target); full-year 2026 variable investment income guidance of ~$1.6B pre-tax ($518M booked in Q1'26); double-digit adjusted-EPS growth target (Q1'26 adjusted EPS +23%); NAIC RBC ratio 379% vs 360% target and Japan ESR mid-range. Management characterized the portfolio as ~95% investment-grade private fixed income and a de-risked CRE book (office down 21% since 2023, 68% average LTV). Treat these as management's own book, half-weighted — they are self-interested and non-GAAP, but they are dated, specific, and consistent with the reported numbers.
10. Catalysts & what to watch
- Next earnings: 2026-08-05 (Q2'26; Street adj-EPS $2.41, revenue ~$19.7B). Key lines: adjusted ROE vs the 15–17% target, VII progress toward the ~$1.6B FY26 guide, and Asia/Group Benefits growth.
- Variable investment income (VII): private-equity/real-estate returns are the swing factor quarter to quarter — the single biggest driver of adjusted-EPS beats and misses.
- Rates & credit: the direction of long rates and any credit deterioration in private credit / commercial mortgage loans directly move book value and earnings.
- Buyback pace: continued share-count reduction is a core part of the per-share thesis — watch authorization use.
- Capital return / RBC: RBC ratio and holdco cash buffer ($3.0–4.0B target range) gate how aggressive buybacks can stay.
Thesis tripwires (what would change the call): a credit event or reserve strengthening in the investment/PRT book; adjusted ROE falling durably below ~13%; a rate shock that materially cuts book value; or a pause in buybacks. Any of these would pull the Tactical buy back to Watch.
11. Key risks
- Investment-portfolio / spread risk (structural, the big one): earnings and book value ride a ~$466B portfolio including private credit, ~$41.5B commercial mortgage loans, structured products, and PRT longevity liabilities. A rate shock or credit cycle hits this fast — the core reason the multiple is low.
- Interest-rate sensitivity: falling rates compress reinvestment yields and spread income over time; sharp moves whipsaw hedges and GAAP earnings.
- GAAP earnings volatility: reported net income swings with marks, making the headline P/E and net income unreliable and occasionally alarming to non-specialist holders.
- Low structural growth: revenue grows low-single-digits; if buybacks slow, per-share growth thins out. This is not a compounder that grows its way out of trouble.
- No expert-KB edge: unlike conviction-track names, there is zero distilled expert coverage — the call rests entirely on quant/fundamentals, so conviction is capped at Low.
- Regulatory/capital: insurance is capital-regulated (RBC, Japan ESR); adverse changes or a downgrade would constrain the capital-return engine that underpins the thesis.
12. Verdict, position sizing & monitoring
Buy — Tactical. MetLife is a cheap (~9× forward adjusted EPS, 2.15× book), well-capitalized (RBC 379%, holdco net-cash), shareholder-friendly (~27% share-count reduction in five years, ~2.5% dividend) global life insurer, breaking out to new highs with healthy technicals. The numbers justify a modest buy on valuation and capital return. But this is a low-growth, rate- and credit-sensitive balance-sheet business with no Synthos expert-KB conviction behind it, so it earns a tactical value/income label, not a core compounder slot.
- Sizing: value/income satellite, ~1–3% of a diversified book — a defensive financial to own for yield, buybacks, and cheapness, not a high-conviction position. Its low beta and index-lagging profile make it a portfolio ballast holding.
- Monitoring: re-underwrite on the §10 tripwires (VII, credit, ROE, buyback pace); formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $90.06.
- Single biggest risk: a rate or credit shock to the ~$466B investment portfolio — the multiple is low precisely because that tail is real.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — MetLife has no Synthos expert-knowledge-base coverage. This note is explicitly fundamentals- and quant-driven; no
claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation) and none is claimed here. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · management guidance from the SEC 8-K/earnings-call presentation filed 2026-05-06. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Adjusted vs GAAP: valuation multiples use the adjusted-earnings (analyst-estimate) series, the honest apples-to-apples metric for an insurer; GAAP net income/EPS is reported separately and is intentionally not used for the P/E anchor.
- Management caveat: MetLife's Q1'26 guidance is management's own book, half-weighted by design (self-interested, non-GAAP).
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").